Integrated Wealth Concepts LLC Reduces Stake in argenx SE (NASDAQ:ARGX)

Integrated Wealth Concepts LLC cut its stake in shares of argenx SE (NASDAQ:ARGX) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 568 shares of the company’s stock after selling 26 shares during the period. Integrated Wealth Concepts LLC’s holdings in argenx were worth $308,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. lifted its stake in argenx by 620.0% during the second quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares during the last quarter. Point72 Hong Kong Ltd purchased a new stake in argenx during the 2nd quarter valued at $76,000. Cromwell Holdings LLC increased its position in shares of argenx by 73.3% in the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC raised its stake in shares of argenx by 47.5% during the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares during the last quarter. Finally, Raymond James Trust N.A. bought a new position in argenx during the 2nd quarter valued at approximately $201,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently commented on ARGX. HC Wainwright reaffirmed a “buy” rating and issued a $617.00 price target on shares of argenx in a research note on Wednesday, November 20th. Piper Sandler lifted their price target on argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Robert W. Baird downgraded shares of argenx from an “outperform” rating to a “neutral” rating and upped their target price for the stock from $515.00 to $650.00 in a research report on Friday, November 1st. Scotiabank raised shares of argenx from a “sector perform” rating to a “sector outperform” rating and raised their target price for the company from $439.00 to $715.00 in a research note on Tuesday, November 5th. Finally, Raymond James reiterated a “strong-buy” rating and set a $605.00 price objective on shares of argenx in a research note on Thursday, October 10th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $635.11.

argenx Trading Down 0.4 %

ARGX opened at $603.40 on Friday. The company has a market capitalization of $36.43 billion, a PE ratio of -685.68 and a beta of 0.59. argenx SE has a 1-year low of $327.73 and a 1-year high of $630.00. The firm’s 50 day simple moving average is $579.49 and its two-hundred day simple moving average is $511.82.

argenx (NASDAQ:ARGX) last released its earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period in the prior year, the firm posted ($1.25) EPS. Equities analysts forecast that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.